Grace Therapeutics, Inc. Cash Flow Statement
GRCE|1 years of annual SEC 10-K data (FY2023-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
Grace Therapeutics, Inc. used $17M in operating cash flow in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.68 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| Net Income | -$9.8M |
| Depreciation & Amortization | $0 |
| Operating Cash Flow | -$17.2M |